Hennion & Walsh Asset Management, Inc. Viridian Therapeutics, Inc.\De Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.1 Billion
- Q4 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 210,899 shares of VRDN stock, worth $3.28 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
210,899
Previous 197,401
6.84%
Holding current value
$3.28 Million
Previous $4.49 Million
9.98%
% of portfolio
0.19%
Previous 0.22%
Shares
7 transactions
Others Institutions Holding VRDN
# of Institutions
200Shares Held
79.4MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$74.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$71.4 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$70.2 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$60.3 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$54.7 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $619M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...